Breast Cancer

Phase 1b data support the promising therapeutic benefit of vepdegestrant/palbociclib in ER-positive breast cancer regardless of ESR1 mutation status.

Data from the INAVO120 trial support the breakthrough therapy designation for inavolisib in PIK3CA-mutated, HR-positive, HER2-negative breast cancer.

Neil M. Iyengar, MD, spoke about the importance of exercise oncology and how it may play a role in positive treatment outcomes for breast cancer.

Neil M. Iyengar, MD, spoke about the potential impact of exercise on patient-reported outcomes in cancer and achieving work-life balance.

Safety data further support datopotamab deruxtecan as a new treatment option in metastatic hormone receptor–positive, HER2-negative breast cancer.

Phase 2 data support the use of fuzuloparib with or without apatinib in HER2-negative metastatic breast cancer harboring BRCA1/2 germline mutations.

Findings suggest that patients with breast cancer and consistently negative circulating tumor DNA tests tend to have improved clinical outcomes.